RESUMEN
Prostate cancer (PCa) is one of the most common malignancies in men. Ribosomal protein L22-like1 (RPL22L1), a component of the ribosomal 60 S subunit, is associated with cancer progression, but the role and potential mechanism of RPL22L1 in PCa remain unclear. The aim of this study was to investigate the role of RPL22L1 in PCa progression and the mechanisms involved. Bioinformatics and immunohistochemistry analysis showed that the expression of RPL22L1 was significantly higher in PCa tissues than in normal prostate tissues. The cell function analysis revealed that RPL22L1 significantly promoted the proliferation, migration and invasion of PCa cells. The data of xenograft tumour assay suggested that the low expression of RPL22L1 inhibited the growth and invasion of PCa cells in vivo. Mechanistically, the results of Western blot proved that RPL22L1 activated PI3K/Akt/mTOR pathway in PCa cells. Additionally, LY294002, an inhibitor of PI3K/Akt pathway, was used to block this pathway. The results showed that LY294002 remarkably abrogated the oncogenic effect of RPL22L1 on PCa cell proliferation and invasion. Taken together, our study demonstrated that RPL22L1 is a key gene in PCa progression and promotes PCa cell proliferation and invasion via PI3K/Akt/mTOR pathway, thus potentially providing a new target for PCa therapy.
Asunto(s)
Próstata , Neoplasias de la Próstata , Masculino , Humanos , Próstata/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Línea Celular Tumoral , Serina-Treonina Quinasas TOR/metabolismo , Neoplasias de la Próstata/patología , Proliferación Celular/genética , Proteínas Ribosómicas/genética , Proteínas Ribosómicas/metabolismo , Movimiento Celular/genéticaRESUMEN
Prostate cancer (PCa) is a challenging issue for men's health worldwide due to its uncontrolled proliferation and high metastatic potential. Increasing evidence has supported plant extracts and natural plant derivatives as promising antitumor therapy with less toxic side effects. Yuanhuacine is an active component isolated from Daphne genkwa and can effectively suppress the tumorigenesis of several cancers. However, its role in PCa remains unclear. In this study, yuanhuacine dose-dependently inhibited the proliferation and induced apoptosis of PCa cells. Moreover, yuanhuacine also restrained the invasion and migration of PCa cells. Mechanically, yuanhuacine decreased the ubiquitination and degradation of p53 protein, and ultimately increased p53 levels, which was regulated by inhibiting the phosphorylation and total protein levels of mouse double minute 2 (MDM2). Moreover, elevation of MDM2 reversed the suppressive efficacy of yuanhuacine in PCa cell viability, invasion, and migration. The network pharmacologic and bioinformatics analysis confirmed that MDM2 might be a common target of D. genkwa and LINC00665. Furthermore, yuanhuacine inhibited LINC00665 expression. Upregulation of LINC00665 reversed yuanhuacine-mediated inhibition in MDM2 protein expression and suppressed p53 levels by enhancing its ubiquitination in yuanhuacine-treated cells. Importantly, the inhibitory effects of yuanhuacine on cell viability and metastatic potential were offset after LINC00665 elevation. Together, the current findings highlight that yuanhuacine may possess tumor-suppressive efficacy by inhibiting LINC00665-mediated MDM2/p53 ubiquitination signaling. Therefore, this study indicates that yuanhuacine may be a promising candidate for the treatment of PCa.
Asunto(s)
Carcinoma , Neoplasias de la Próstata , ARN Largo no Codificante , Humanos , Masculino , Ratones , Animales , Proteínas Proto-Oncogénicas c-mdm2 , Proteína p53 Supresora de Tumor/metabolismo , ARN Largo no Codificante/metabolismo , Próstata/metabolismo , Ubiquitinación , Neoplasias de la Próstata/metabolismo , Carcinogénesis/metabolismo , Línea Celular Tumoral , Apoptosis , Proliferación Celular/genéticaRESUMEN
BACKGROUND: There are differences in survival between high-and low-grade Upper Tract Urothelial Carcinoma (UTUC). Our study aimed to develop a nomogram to predict overall survival (OS) of patients with high- and low-grade UTUC after tumor resection, and to explore the difference between high- and low-grade patients. METHODS: Patients confirmed to have UTUC between 2004 and 2015 were selected from the Surveillance, Epidemiology and End Results (SEER) database. The UTUCs were identified and classified as high- and low-grade, and 1-, 3- and 5-year nomograms were established. The nomogram was then validated using the Chinese multicenter dataset (patients diagnosed in Shandong, China between January 2010 and October 2020). RESULTS: In the high-grade UTUC patients, nine important factors related to survival after tumor resection were identified to construct nomogram. The C index of training dataset was 0.740 (95% confidence interval [CI]: 0.727-0.754), showing good calibration. The C index of internal validation dataset was 0.729(95% CI:0.707-0.750). On the other hand, Two independent predictors were identified to construct nomogram of low-grade UTUC. The C index was 0.714 (95% CI: 0.671-0.758) for the training set,0.731(95% CI:0.670-0.791) for the internal validation dataset. Encouragingly, the nomogram was clinically useful and had a good discriminative ability to identify patients at high risk. CONCLUSION: We constructed a nomogram and a corresponding risk classification system predicting the OS of patients with an initial diagnosis of high-and low-grade UTUC.
Asunto(s)
Modelos Estadísticos , Nomogramas , Programa de VERF/estadística & datos numéricos , Neoplasias de la Vejiga Urinaria/mortalidad , Factores de Edad , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Masculino , Estadificación de Neoplasias , Estudios Retrospectivos , Tasa de Supervivencia , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/cirugíaRESUMEN
3D Fe3SnC/C hybrid nanofibers are proposed as a novel high-performance microwave absorber. At only 20 wt% filler loading, the optimal reflection loss reaches -119.2 dB at 17.1 GHz and the effective absorption bandwidth is 7.4 GHz with a thickness of 2.3 mm, outperforming most of the reported absorbers.
RESUMEN
Glioma is the most aggressive malignant tumor in the adult central nervous system. Abnormal long noncoding RNA (lncRNA) FOXD2-AS1 expression was associated with tumor development. However, the possible role of FOXD2-AS1 in the progression of glioma is not known. In the present study, we used in vitro and in vivo assays to investigate the effect of abnormal expression of FOXD2-AS1 on glioma progression and to explore the mechanisms. FOXD2-AS1 was upregulated in glioma tissue, cells, and sphere subpopulation. Upregulation of FOXD2-AS1 was correlated with poor prognosis of glioma. Downregulation of FOXD2-AS1 decreased cell proliferation, migration, invasion, stemness, and epithelial-mesenchymal transition (EMT) in glioma cells and inhibited tumor growth in transplanted tumor. We also revealed that FOXD2-AS1 was mainly located in cytoplasm and microRNA (miR)-185-5p both targeted FOXD2-AS1 and CCND2 messenger RNA (mRNA) 3'-untranslated region (3'-UTR). miR-185-5p was downregulated in glioma tissue, cells, and sphere subpopulation. Downregulation of miR-185-5p was closely correlated with poor prognosis of glioma patients. In addition, miR-185-5p mimics decreased cell proliferation, migration, invasion, stemness, and EMT in glioma cells. CCND2 was upregulated in glioma tissue, cells, and sphere subpopulation. Upregulation of CCND2 was closely correlated with poor prognosis of glioma patients. CCND2 knockdown decreased cell proliferation, migration, invasion, and EMT in glioma cells. In glioma tissues, CCND2 expression was negatively associated with miR-185-5p, but positively correlated with FOXD2-AS1. FOXD2-AS1 knockdown and miR-185-5p mimics decreased CCND2 expression. Inhibition of miR-185-5p suppressed FOXD2-AS1 knockdown-induced decrease of CCND2 expression. Overexpression of CCND2 suppressed FOXD2-AS1 knockdown-induced inhibition of glioma malignancy. Taken together, our findings highlight the FOXD2-AS1/miR-185-5p/CCND2 axis in the glioma development.
Asunto(s)
Ciclina D2/genética , Glioma/genética , MicroARNs/genética , ARN Largo no Codificante/genética , Apoptosis/genética , Carcinogénesis/genética , Proliferación Celular/genética , Progresión de la Enfermedad , Transición Epitelial-Mesenquimal/genética , Femenino , Regulación Neoplásica de la Expresión Génica/genética , Glioma/patología , Xenoinjertos , Humanos , Masculino , Transducción de Señal/genéticaRESUMEN
In photon upconversion (UC) based on triplet-triplet annihilation, the upconversion photoluminescent quantum yield (UC-PLQY) depends on the excitation power density in a way that can be described by a single figure of merit. This figure of merit, the threshold value, allows the excitation power density required for efficient UC-PLQY to be compared between different triplet-triplet annihilation systems. Here, we investigate the excitation power density dependence of two-photon UC processes in a series of four lanthanide-doped inorganic host materials (oxides, fluorides, and chlorides) all doped with 18 mol % Yb3+ sensitizer ions and 2 mol % Er3+ activator ions. We demonstrate that an analogous figure of merit, which we call the critical power density (CPD), accurately describes the UC power dependence of these samples. Better CPD values are obtained when the lifetime of the intermediate states is long. The UC-PLQY at the CPD is linked to the saturation UC-PLQY. Thus, a measurement of the UC-PLQY at this low power density can be used to estimate the theoretical saturation UC-PLQY in the absence of deleterious effects such as laser-induced heating. This is compared to another method to estimate the saturation based on the CPD model, namely, taking half of the level's PLQY under direct excitation. Our careful analysis of the upconversion spectra as a function of excitation power density gives several insights into the differing upconversion pathways in the hosts and proves to be a useful tool for their comparison.
RESUMEN
We report a 30 cm long Nd3+/Yb3+ co-doped silica glass fiber amplifier with well-maintained broadband gain through simultaneous dual-laser pumping at 808 and 975 nm. By controlling the ratio of the pump power at 975 (P975) and 808 nm (P808), the emission band of Yb3+/Nd3+ and the energy transfer efficiency of Nd3+âYb3+ can be well controlled; thus, a tunable broadband and flat gain in the range of 1036-1080 nm are obtained. The theoretical calculation of the energy transfer efficiency of Nd3+âYb3+ with dual-laser pumping of 808 and 975 nm explains well the mechanism of broadband and flat gain formation in the Nd3+/Yb3+ co-doped fiber.
RESUMEN
The laser behavior of a centimeter-scale Er3+/Al3+ codoped silica fiber with core numerical aperture and core diameter of 0.15 and 8 µm, respectively, is reported. The core glass was prepared by the sol-gel method combined with high-temperature sintering; it contained Er3+ ion concentration as high as 1.32×1020 ions/cm3 and an Al/Er mole ratio of 10. The high doping homogeneity of Er3+ ions in the fiber core was confirmed by an electron probe microanalyzer element scanning, long Er3+: I13/24 emission lifetime of 11.4 ms, and low refractive index fluctuation of fiber core (±1×10-4). The signal gain of fibers with 4.6 cm, 10 cm, and 16 cm lengths was tested in the 1500-1620 nm range. A gain of 7 dB is achieved at 1560 nm in a 16-cm-long EDF under 230 mW pump power. Aimed for CO2 sensor application, the laser behavior of Er/Al codoped fiber was tested at 1572 nm. A slope efficiency of 12% and an output power of 15 mW were achieved in a 10-cm-long fiber under 166 mW absorbed pump power. The newly developed silica fiber is promising for use in high-repetition-rate lasers.
RESUMEN
We develop an efficient green upconversion (UC) ß-NaYF4:20%Yb3+,2%Er3+ microcrystal with well controlled morphology and size by hydrothermal method using two different chelating agents of CIT and EDTA-2Na via a simple ion-exchange reaction. Importantly, the UC emission efficiency of newly developed CIT and EDTA-2Na ß-NaYF4:20%Yb3+,2%Er3+ microcrystals is almost as strong as that of commercial counterpart by solid-state method. A proof-of-concept ß-NaYF4:20%Yb3+,2%Er3+ microcrystal waveguide is demonstrated to extend their applications in modern micro-optoelectronics. The local ion-redistribution process during the ion-exchange reaction, which effectively disperses the locally clustered Yb3+, accounts for the enormously enhanced UC emission in ß-NaYF4:20%Yb3+,2%Er3+ microcrystals.
RESUMEN
Output power scaling of single mode large mode area (LMA) photonic crystal fiber (PCF) amplifiers urgently requires the low refractive index of Yb3+-doped silica glasses whilst maintaining high optical homogeneity. In this paper, we report on a promising alternative Yb3+/Al3+/F-/P5+-co-doped silica core-glass (YAFP), which is prepared by modified sol-gel method developed by our group and highly suitable for fabricating high power LMA PCF amplifiers. By controlling the doping combinations of Al3+/F-/P5+ in Yb3+-doped silica glass,it not only ensures low refractive index (RI) but also maintains the excellent optical homogeneity and spectroscopic properties of Yb3+. The spectroscopic properties of Yb3+ ions have not deteriorated by the co-doping of F- and P5+ in YAFP glass compared with that of Yb3+/Al3+ co-doped silica glass. A large-size (â5 mm × 90 mm) YAFP silica-core glass rod with low average RI difference of 2.6 × 10-4 (with respect to pure silica glass), and low radial and axial RI fluctuations of ~2 × 10-4, was prepared. A LMA PCF with 50 µm core diameter was obtained by stack-capillary-draw techniques using YAFP core glass. Its core NA is 0.027. An average amplified power of 97 W peaking at 1030 nm and light-light efficiency of 54% are achieved from a 6.5 m long PCF in the pulse amplification laser experiment. Meanwhile, quasi-single-mode transmission is obtained with laser beam quality factor M2 of 1.4.
RESUMEN
OBJECTIVE: To compare the efficacy of combination therapy with an alpha-blocker and an anticholinergic to monotherapy with an alpha blocker on lower urinary tract symptoms (LUTS) following brachytherapy in prostate cancer patients. MATERIAL AND METHODS: A total of 124 patients that had been clinically diagnosed with localized prostate cancer and underwent prostate brachytherapy were enrolled in the present study. Patients were randomized and allocated to two groups, including 60 to the combination group (tamsulosin 0.2 mg/day and trospium chloride 20 mg twice daily) and 64 to the monotherapy group (tamsulosin 0.2 mg/day). Treatment began 1 day after brachytherapy and continued for 6 months. LUTS were compared between the two groups using the total International Prostate Symptom Score (IPSS), storage and voiding IPSS subscores, quality of life (QoL) scores, maximum flow rate (Qmax), and postvoid residual (PVR) urine volume at 1, 3, 6, and 12 months after implantation. RESULTS: In all, 111 patients were ultimately analyzed in the study. Compared with pretreatment scores, a significant increase in total IPSS was found at 1, 3, and 6 months in both groups, but no statistically significant differences were observed between the two groups. The combination therapy group showed a greater decrease in the IPSS storage score compared with the monotherapy group at 1, 3, and 6 months (p = 0.031, 0.030 and 0.042, respectively). Patients receiving tamsulosin plus trospium chloride also showed significant improvements in QoL at 1 and 3 months compared with tamsulosin alone (P = 0.039, P = 0.047). Between the two groups, there was no significant difference in IPSS voiding score, Qmax, and PVR from baseline to each point of the study period. CONCLUSIONS: Combination therapy with tamsulosin and trospium chloride helped to improve IPSS storage symptoms and Qol scores in prostate brachytherapy patients with LUTS compared with tamsulosin monotherapy.
Asunto(s)
Bencilatos/uso terapéutico , Braquiterapia/efectos adversos , Síntomas del Sistema Urinario Inferior/tratamiento farmacológico , Nortropanos/uso terapéutico , Neoplasias de la Próstata/radioterapia , Traumatismos por Radiación/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Anciano , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Quimioterapia Combinada , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Calidad de Vida , Tamsulosina , Urodinámica/efectos de los fármacos , Urodinámica/efectos de la radiaciónRESUMEN
This study aims to evaluate microRNA-383 (miR-383) expression level in glioma cells and its influences on proliferation, migration, invasion, apoptosis, and cell cycle in glioma cells. miR-383 expression levels were determined by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). Thirty BALB/c-nu mice were randomly assigned into three groups: U87-miR-383 group, vector-control group, and blank group. Tumorigenicity experiment was conducted to confirm the function of miR-383. U251 and U87 glioma cells were divided into three groups: non-transfected control cells (NT group), glioma cells transfected with miR-383 (miR-383 group), and glioma cells transfected with negative sequence (NC group). Transfection efficiency was measured by qRT-PCR. Cell counting kit-8 (CCK-8) assay was used to detect cell proliferation. Cell migration and invasion were examined by utilizing a Transwell chamber. Cell cycle and apoptosis were analyzed by flow cytometry. The qRT-PCR results revealed that miR-383 expression was down-regulated in human glioma cells, and was negatively related to the pathological grading of glioma. The rates of tumor growth in vector-control group and blank group were significantly faster than that in U87-miR-383 group, and the average tumor volume and weight in vector-control group and blank group were increased as compared with U87-miR-383 group. Additionally, miR-383 levels in miR-383 group were higher than those in NT group and NC group. CCK-8 assay indicated lower cell viability in miR-383 group as compared with NT group and NC group. Flow cytometry implied that the percentages of cells in miR-383 group reduced, while the cell apoptosis rate enhanced compared with NT group and NC group. In conclusion, our findings suggest that miR-383 expression is down-regulated in glioma cells, inhibiting cell proliferation, migration, and invasion, affecting the cell cycle, and inducing cell apoptosis.
Asunto(s)
Apoptosis , Neoplasias Encefálicas/patología , Encéfalo/metabolismo , Movimiento Celular , Proliferación Celular , Glioma/patología , MicroARNs/genética , Adolescente , Adulto , Anciano , Animales , Western Blotting , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/metabolismo , Estudios de Casos y Controles , Ciclo Celular , Femenino , Citometría de Flujo , Regulación Neoplásica de la Expresión Génica , Glioma/genética , Glioma/metabolismo , Humanos , Técnicas para Inmunoenzimas , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Persona de Mediana Edad , Invasividad Neoplásica , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto , Adulto JovenRESUMEN
OBJECTIVE: To evaluate the short-term therapeutic effects of low-dose cytarabine plus surgical resection on elderly patients with trigeminal nerve tumor and to observe the safety. METHODS: A total of 120 elderly patients with trigeminal nerve tumor were divided into a treatment group and a control group by random draw (n=60), and both groups were subjected to resection by stereotactic image-guided endoscopic nasal surgery. Afterwards, the control group was administered with high-dose cytarabine while the treatment group was given low-dose cytarabine for 14 days. RESULTS: Both groups completed treatment, but the effective rate of the treatment group (96.7%) was significantly higher than that of the control group (83.3%) (P < 0.05). The pain scores of the two groups were similar at T0, T1 and T2, but the score of the treatment group at T2 was significantly different from those at T0 and T1 (P < 0.05). During treatment, the treatment group was significantly less prone to complications such as headache, vomiting, vision impairment, nausea and local swelling than the control group (P < 0.05). During three months of follow-up, the appetite, sleep and daily living scores were significantly higher than those of the control group (P < 0.05). CONCLUSION: Stereotactic image-guided surgery was able to treat trigeminal nerve tumor well, and the effect was enhanced by low-dose cytarabine that improved postoperative outcomes and quality of life by dramatically decreasing complications.
RESUMEN
We conducted a case-control study to assess the role of three single-nucleotide polymorphisms (SNPs) in excision repair cross-complementation group 1 (ERCC1) and two SNPs in excision repair cross-complementation group 2 (ERCC2) on the glioma risk in a Chinese population, and investigate the gene-environmental interaction for the cancer risk. A 1:2 matched case-control study was conducted. Logistic regression analysis revealed that individuals carrying ERCC1 rs2298881 CC genotype were associated with risk of glioma when compared with AA genotype carriers. The significant associations of ERCC1 rs2298881 polymorphism with glioma susceptibility were observed in both the dominant and the recessive models. In a stratification analysis, we found that ERCC1 rs2298881 variants showed an increased association with the risk of glioma in males, ever smokers, and high-grade glioma cases. In conclusion, our study suggests that ERCC1 rs2298881 polymorphism is associated with risk of glioma in codominant, dominant, and recessive models, especially in males, smokers, and high-grade glioma cases. This finding could be useful in revealing the genetic characteristics of glioma and suggests more effective strategies for prevention and treatment.
Asunto(s)
Neoplasias Encefálicas/genética , Proteínas de Unión al ADN/genética , Endonucleasas/genética , Predisposición Genética a la Enfermedad , Glioma/genética , Polimorfismo de Nucleótido Simple , Proteína de la Xerodermia Pigmentosa del Grupo D/genética , Adulto , Anciano , Neoplasias Encefálicas/etiología , Estudios de Casos y Controles , Reparación del ADN , Femenino , Genotipo , Glioma/etiología , Humanos , Modelos Logísticos , Masculino , Persona de Mediana EdadRESUMEN
Prostate cancer (PCa) is the most common malignancy among men worldwide. The cell division cycle 42 effector protein 4 (CDC42EP4) functions downstream of CDC42, yet its role and molecular mechanisms in PCa remain unexplored. This study aimed to elucidate the role of CDC42EP4 in the progression of PCa and its underlying mechanisms. Bioinformatical analysis indicated that CDC42EP4 expression was significantly lower in PCa tissue compared to normal prostate tissue. Cellular phenotyping analysis suggested that CDC42EP4 markedly inhibited the proliferation, migration, and invasion of PCa cells. Xenograft tumor assays further demonstrated that CDC42EP4 suppressed the growth of PCa cells in vivo. Mechanistically, the study established that CDC42EP4 inhibited the ERK pathway in PCa cells. Additionally, the ERK pathway inhibitor PD0325901 was employed, revealing that PD0325901 significantly nullified the effects of CDC42EP4 on PCa cell proliferation, migration, and invasion. Collectively, our findings demonstrate that CDC42EP4 acts as a critical tumor suppressor gene, inhibiting PCa cell proliferation, migration, and invasion through the ERK pathway, thereby presenting potential targets for PCa therapy.
Asunto(s)
Movimiento Celular , Proliferación Celular , Sistema de Señalización de MAP Quinasas , Neoplasias de la Próstata , Masculino , Humanos , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/genética , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Animales , Línea Celular Tumoral , Ratones , Progresión de la Enfermedad , Ratones Desnudos , Regulación Neoplásica de la Expresión Génica , Invasividad Neoplásica/genéticaRESUMEN
Ultrabroad near-infrared (NIR) photoluminescence from Ni2+-centers in nanocrystalline Ba-Al titanate glass ceramics was studied by temperature-dependent static and dynamic photoluminescence spectroscopy in the regime of 10 to 300 K. Photoluminescence covers the spectral range of about 1100 nm to >1600 nm with a typical bandwidth (FWHM) greater than 300 nm. For UV-LED excitation at 352 nm, an internal quantum efficiency of 65% is obtained. The excited state lifetime τ at room temperature is 39 µs. The stimulated emission cross section σ(em) is 8.5×10(-20) cm2, resulting in a practical figure of merit, σ(em) * τ, of 3.3×10(-24) cm2 s at room temperature. These properties suggest suitability as a broadband gain medium for tunable lasers and optical amplifiers.
RESUMEN
Objective: To investigate the clinical efficacy of holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH) with prostatic inflammation (PI). Methods: We prospectively collected and followed up data on patients with BPH who underwent HoLEP at the Affiliated Hospital of Weifang Medical University between July 2021 and July 2022. According to the postoperative pathological results, the patients were divided into two groups: BPH without PI group (BPH group) and BPH with PI group. Statistical analysis was performed on clinical data, including age and body mass index (BMI), prostate volume (PV), postoperative residual urine volume (PVR), preoperative serum total prostate-specific antigen (tPSA), serum-free prostate-specific antigen (fPSA), preoperative and postoperative maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS) before and 3 months after surgery, quality of life index (QoL) before and 3 months after surgery, and postoperative complications. Results: A total of 41 patients were included in this study, including 16 in the BPH group and 25 in the BPH with PI group. There were no significant differences in preoperative age, BMI, PV, PVR, tPSA, fPSA, and f/tPSA between the BPH and BPH with PI groups (P > 0.05). The preoperative mean Qmax of the BPH and BPH with PI groups were 9.44 ± 2.449 and 7.52 ± 2.946 [mean ± standard deviation (SD)] ml/s, mean IPSS were 17.75 ± 5.335 and 24.24 ± 5.861 (mean ± SD), and mean QoL were 4.13 ± 0.806 and 4.48 ± 0.8 (mean ± SD), respectively. The postoperative mean Qmax of the BPH and BPH with PI groups were 20.38 ± 4.787 and 14.32 ± 3.827 (mean ± SD) ml/s, mean IPSS were 2.69 ± 1.25 and 5.84 ± 3.579 (mean ± SD), and mean QoL were 0.13 ± 0.342 and 0.92 ± 0.759 (mean ± SD), respectively. In both groups, Qmax significantly increased (P < 0.05) and IPSS and QoL significantly decreased after HoLEP (P < 0.05). Before and after surgery, the Qmax in the BPH with PI group was lower than that in the BPH group, and the IPSS and QoL levels in the BPH with PI group were higher than those in the BPH group (P < 0.05). Compared with the BPH group, the increase in Qmax in the BPH with PI group was smaller and the decrease in IPSS was larger (P < 0.05), but the variation in QoL was not statistically significant (P > 0.05). Conclusion: Improvements in Qmax, IPSS, and QoL in BPH patients with PI after HoLEP surgery were lower than those in BPH patients alone. PI may be a predictor of a worse response to surgical treatment. However, more multicenter randomized controlled trials with larger samples and long-term follow-up are needed to verify this.
RESUMEN
We report on photoluminescence of vanadium-doped lithium zinc silicate glasses and corresponding nanocrystalline Li2ZnSiO4 glass ceramics as broadband UV-to-VIS photoconverters. Depending on dopant concentration and synthesis conditions, VIS photoemission from [VO4]3 is centered at 550-590 nm and occurs over a bandwidth (FWHM) of ~250 nm. The corresponding excitation band covers the complete UV-B to UV-A spectral region. In as-melted glasses, the emission lifetime is about 34 µs up to a nominal dopant concentration of 0.5 mol%. In the glass ceramic, it increases to about 45 µs. For higher dopant concentration, a sharp drop in emission lifetime was observed, what is interpreted as a result of concentration quenching. Self-quenching is further promoted by energy transfer to V4+ centers (2<Ðt4â2Ðt3). Partitioning of vanadium into V5+ and V4+ was examined by electron paramagnetic resonance and X-ray photoelectron spectroscopy. Suppression of V5+-reduction requires careful adjustment of the optical basicity of the host glass and/or synthesis conditions.
Asunto(s)
Cerámica , Vidrio , Luz , Litio/química , Óptica y Fotónica/métodos , Silicatos/química , Zinc/química , Diseño de Equipo , Ensayo de Materiales , Rayos UltravioletaRESUMEN
The abnormal neurites have long been regarded as the main player contributing to the poor outcome of patients with subarachnoid hemorrhage (SAH). (-)-Eigallocatechin-3-gallate (EGCG), the major biological component of tea catechin, exhibited strong neuroprotective effects against central nervous system diseases; however, the role of EGCG-mediated neurite outgrowth after SAH has not been delineated. Here, the effect of reactive oxygen species (ROS)/integrin ß1/FAK/p38 pathway on neurite outgrowth was investigated. As expected, oxyhemoglobin- (OxyHb-) induced excessive ROS level was significantly reduced by EGCG as well as antioxidant N-acetyl-l-cysteine (NAC). Consequently, the expression of integrin ß1 was significantly inhibited by EGCG and NAC. Meanwhile, EGCG significantly inhibited the overexpression of phosphorylated FAK and p38 to basal level after SAH. As a result, the abnormal neurites and cell injury were rescued by EGCG, which eventually increased energy generation and neurological score after SAH. These results suggested that EGCG promoted neurite outgrowth after SAH by inhibition of ROS/integrin ß1/FAK/p38 signaling pathway. Therefore, EGCG might be a new pharmacological agent that targets neurite outgrowth in SAH therapy.
RESUMEN
Intense photoluminescence was observed from mixed-valence Eu-doped nanocrystalline BaAl2Si2O8/LaBO3 glass ceramics. For preparation in air, the ratio between Eu3+ and Eu2+ luminescence depends on synthesis temperature. XRD, TEM and IR absorption spectra were employed to characterize the crystallization process and structural properties of the precursor glass and corresponding glass ceramics. When annealed at 950 °C, the material exhibited photoluminescence more than ten times stronger than was found in its glassy state. Spectroscopic data indicate that during such a heat treatment, even in air, a significant part of the Eu3+ ions is reduced to Eu2+. Lifetime of the 5D0 state of Eu3+ increases with increasing heat treatment temperature. Eu3+ species are largely incorporated on La3+ sites in LaBO3 crystallites whereas Eu2+ locates on Ba2+ sites in the hexacelsian phase. A mechanism for the internal reduction of Eu3+ to Eu2+ is proposed. Spectroscopic properties of the material suggest application in additive luminescent light generation.